Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 804659, 12 pages
http://dx.doi.org/10.1155/2015/804659
Research Article

A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion

1Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino, Via P. Giuria 9, 10125 Torino, Italy
2Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università di Torino, Via Nizza 52, 10126 Torino, Italy
3ININCA-CONICET, Buenos Aires, Argentina

Received 15 December 2014; Accepted 13 February 2015

Academic Editor: Trevor A. Mori

Copyright © 2015 Fausto Chiazza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Pérez-González and A. Galano, “OH radical scavenging activity of edaravone: mechanism and kinetics,” Journal of Physical Chemistry B, vol. 115, no. 5, pp. 1306–1314, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Toyoda, K. Fujii, M. Kamouchi et al., “Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion,” Journal of the Neurological Sciences, vol. 221, no. 1-2, pp. 11–17, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Tsujita, H. Shimomura, H. Kawano et al., “Effects of edaravone on reperfusion injury in patients with acute myocardial infarction,” The American Journal of Cardiology, vol. 94, no. 4, pp. 481–484, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Watanabe, M. Tahara, and S. Todo, “The novel antioxidant edaravone: from bench to bedside,” Cardiovascular Therapeutics, vol. 26, no. 2, pp. 101–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Kamouchi, H. Sakai, Y. Kiyohara, K. Minematsu, K. Hayashi, and T. Kitazono, “Acute kidney injury and edaravone in acute ischemic stroke: the fukuoka stroke registry,” Journal of Stroke and Cerebrovascular Diseases, vol. 22, no. 8, pp. e470–e476, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Tahara, M. Nakayama, M. B. Jin et al., “A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation,” Transplantation, vol. 80, no. 2, pp. 213–221, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Matsuyama, T. Hayama, K. Funao et al., “Treatment with edaravone improves the survival rate in renal warm ischemia-reperfusion injury using rat model,” Transplantation Proceedings, vol. 38, no. 7, pp. 2199–2200, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Sueishi, K. Mishima, K. Makino et al., “Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats,” European Journal of Pharmacology, vol. 451, no. 2, pp. 203–208, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Iguchi, M. Nishikawa, B. Chang et al., “Edaravone inhibits acute renal injury and cyst formation in cisplatin-treated rat kidney,” Free Radical Research, vol. 38, no. 4, pp. 333–341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Bellomo, J. A. Kellum, and C. Ronco, “Acute kidney injury,” The Lancet, vol. 380, no. 9843, pp. 756–766, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. P. N. A. Martins, A. Chandraker, and S. G. Tullius, “Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment,” Transplant International, vol. 19, no. 5, pp. 351–359, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. D. S. A. Majid and L. G. Navar, “Nitric oxide in the control of renal hemodynamics and excretory function,” The American Journal of Hypertension, vol. 14, no. 6, pp. 74S–82S, 2001. View at Google Scholar · View at Scopus
  13. E. L. Rhoden, C. R. Rhoden, M. L. Lucas, L. Pereira-Lima, C. Zettler, and A. Belló-Klein, “The role of nitric oxide pathway in the renal ischemia-reperfusion injury in rats,” Transplant Immunology, vol. 10, no. 4, pp. 277–284, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Chegaev, L. Lazzarato, B. Rolando et al., “NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization,” Journal of Pineal Research, vol. 42, no. 4, pp. 371–385, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Cena, K. Chegaev, S. Balbo et al., “Novel antioxidant agents deriving from molecular combination of vitamin C and NO-donor moieties,” Bioorganic and Medicinal Chemistry, vol. 16, no. 9, pp. 5199–5206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Chegaev, C. Cena, M. Giorgis et al., “Edaravone derivatives containing NO-donor functions,” Journal of Medicinal Chemistry, vol. 52, no. 2, pp. 574–578, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Collino, E. Benetti, G. Miglio et al., “Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats,” Free Radical Biology and Medicine, vol. 50, no. 2, pp. 345–353, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. N. S. A. Patel, S. Cuzzocrea, M. Collino et al., “The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo,” European Journal of Pharmacology, vol. 562, no. 1-2, pp. 148–154, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Collino, M. Rogazzo, A. Pini et al., “Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury,” Journal of Cellular and Molecular Medicine, vol. 17, no. 11, pp. 1494–1505, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Doi, Y. Suzuki, A. Nakao, T. Fujita, and E. Noiri, “Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney,” Kidney International, vol. 65, no. 5, pp. 1714–1723, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Li, A.-Z. Xia, and S.-H. Xing, “Protective effect of edaravone against renal ischemia/reperfusion injury and compared with ischemic postconditioning in rats,” Yaoxue Xuebao, vol. 45, no. 7, pp. 840–848, 2010. View at Google Scholar · View at Scopus
  22. C. Bazzi, C. Petrini, V. Rizza et al., “Urinary N-acetyl-β-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis,” Nephrology Dialysis Transplantation, vol. 17, no. 11, pp. 1890–1896, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Mishra, M. A. Qing, A. Prada et al., “Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury,” Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2534–2543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. N. S. A. Patel, H. L. Kerr-Peterson, M. Brines et al., “Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury,” Molecular Medicine, vol. 18, pp. 719–727, 2012. View at Google Scholar · View at Scopus
  25. M. Kenan Kinaci, N. Erkasap, A. Kucuk, T. Koken, and M. Tosun, “Effects of quercetin on apoptosis, NF-kappaB and NOS gene expression in renal ischemia/reperfusion injury,” Experimental and Therapeutic Medicine, vol. 3, no. 2, pp. 249–254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Zhang, M. Komine-Kobayashi, R. Tanaka, M. Liu, Y. Mizuno, and T. Urabe, “Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain,” Stroke, vol. 36, no. 10, pp. 2220–2225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Higashi, D. Jitsuiki, K. Chayama, and M. Yoshizumi, “Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases,” Recent Patents on Cardiovascular Drug Discovery, vol. 1, no. 1, pp. 85–93, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Tamamura, M. Saito, Y. Kinoshita et al., “Protective effect of edaravone, a free-radical scavenger, on ischaemia-reperfusion injury in the rat testis,” BJU International, vol. 105, no. 6, pp. 870–876, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Shimoda, Y. Iwasaki, T. Okada, and K. Kubota, “Edaravone inhibits apoptosis caused by ischemia/ reperfusion injury in a porcine hepatectomy model,” World Journal of Gastroenterology, vol. 18, no. 27, pp. 3520–3526, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Kara, Y. K. Daglioglu, Y. Kuyucu, A. Tuli, and O. Tap, “The effect of edaravone on ischemia-reperfusion injury in rat ovary,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 162, no. 2, pp. 197–202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Urbschat, K. Zacharowski, N. Obermüller et al., “The small fibrinopeptide Bβ15-42 as renoprotective agent preserving the endothelial and vascular integrity in early ischemia reperfusion injury in the mouse kidney,” PLoS ONE, vol. 9, no. 1, Article ID e84432, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Bellinger, J. S. Bean, M. A. Rader et al., “Concordant changes of plasma and kidney microRNA in the early stages of acute kidney injury: time course in a mouse model of bilateral renal ischemia-reperfusion,” PLoS ONE, vol. 9, no. 4, Article ID e93297, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. R. di Paola, D. Impellizzeri, P. Mondello et al., “Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice,” Shock, vol. 38, no. 4, pp. 356–366, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. C. L. Edelstein, H. Ling, and R. W. Schrier, “The nature of renal cell injury,” Kidney International, vol. 51, no. 5, pp. 1341–1351, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. B. R. Clapp, A. D. Hingorani, R. K. Kharbanda et al., “Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress,” Cardiovascular Research, vol. 64, no. 1, pp. 172–178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Ogita and J. K. Liao, “Endothelial function and oxidative stress,” Endothelium, vol. 11, no. 2, pp. 123–132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Caramelo, G. Espinosa, F. Manzarbeitia et al., “Role of endothelium-related mechanisms in the pathophysiology of renal ischemia/reperfusion in normal rabbits,” Circulation Research, vol. 79, no. 5, pp. 1031–1038, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Schwartz, M. Mendonca, I. Schwartz et al., “Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats,” The Journal of Clinical Investigation, vol. 100, no. 2, pp. 439–448, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Schramm, E. Heidbreder, A. Schmitt et al., “Role of L-arginine-derived NO in ischemic acute renal failure in the rat,” Renal Failure, vol. 16, no. 5, pp. 555–569, 1994. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Linas, D. Whittenburg, and J. E. Repine, “Nitric oxide prevents neutrophil-mediated acute renal failure,” The American Journal of Physiology—Renal Physiology, vol. 272, no. 1, pp. F48–F54, 1997. View at Google Scholar · View at Scopus
  41. P. Tripatara, N. S. A. Patel, A. Webb et al., “Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase,” Journal of the American Society of Nephrology, vol. 18, no. 2, pp. 570–580, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. L. C. Cantley, “The phosphoinositide 3-kinase pathway,” Science, vol. 296, no. 5573, pp. 1655–1657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. E. A. El Eter and A. Aldrees, “Inhibition of proinflammatory cytokines by SCH79797, a selective protease-activated receptor 1 antagonist, protects rat kidney against ischemia-reperfusion injury,” Shock, vol. 37, no. 6, pp. 639–644, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. H.-S. Jang, J. Kim, K. Y. Kim, J. I. Kim, M. H. Cho, and K. M. Park, “Previous ischemia and reperfusion injury results in resistance of the kidney against subsequent ischemia and reperfusion insult in mice; A role for the Akt signal pathway,” Nephrology Dialysis Transplantation, vol. 27, no. 10, pp. 3762–3770, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. D. E. Choi, J. Y. Jeong, B. J. Lim et al., “Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats,” Renal Physiology—American Journal of Physiology, vol. 297, pp. F362–F370, 2009. View at Google Scholar
  46. A. Satake, M. Takaoka, M. Nishikawa et al., “Protective effect of 17β-estradiol on ischemic acute renal failure through the PI3K/Akt/eNOS pathway,” Kidney International, vol. 73, no. 3, pp. 308–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Liu, H. Chen, B. Zhan et al., “Attenuation of reperfusion injury by renal ischemic postconditioning: the role of NO,” Biochemical and Biophysical Research Communications, vol. 359, no. 3, pp. 628–634, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. A.-A. M. Hussein, N. Barakat, A. Awadalla, and A. A. Shokeir, “Systemic and renal haemodynamic changes in renal schemia/reperfusion injury: impact of erythropoietin,” Canadian Journal of Physiology and Pharmacology, vol. 90, no. 11, pp. 1535–1543, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. P. K. Chatterjee, N. S. A. Patel, E. O. Kvale et al., “Inhibition of inducible nitric oxide synthase reduces renal ischemia/reperfusion injury,” Kidney International, vol. 61, no. 3, pp. 862–871, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. K. K. Donnahoo, B. D. Shames, A. H. Harken, and D. R. Meldrum, “The role of tumor necrosis factor in renal ischemia-reperfusion injury,” The Journal of Urology, vol. 162, no. 1, pp. 196–203, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. L. M. Walker, P. D. Walker, S. Z. Imam, S. F. Ali, and P. R. Mayeux, “Evidence for peroxynitrite formation in renal ischemia-reperfusion injury: studies with the inducible nitric oxide synthase inhibitor L-N6-(1-iminoethyl)lysine,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 1, pp. 417–422, 2000. View at Google Scholar · View at Scopus
  52. K. M. Park, J.-Y. Byun, C. Kramers, J. I. Kim, P. L. Huang, and J. V. Bonventre, “Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney,” The Journal of Biological Chemistry, vol. 278, no. 29, pp. 27256–27266, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Torras, I. Herrero-Fresneda, N. Lloberas, M. Riera, J. M. Cruzaoo, and J. M. Grinyo, “Promising effects of ischemic preconditioning in renal transplantation,” Kidney International, vol. 61, no. 6, pp. 2218–2227, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. J. I. Kim, H.-S. Jang, and K. M. Park, “Endotoxin-induced renal tolerance against ischemia and reperfusion injury is removed by iNOS, but not eNOS, gene-deletion,” BMB Reports, vol. 43, no. 9, pp. 629–634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. M. S. Goligorsky, S. V. Brodsky, and E. Noiri, “Nitric oxide in acute renal failure: NOS versus NOS,” Kidney International, vol. 61, no. 3, pp. 855–861, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. M. S. Paller, J. R. Hoidal, and T. F. Ferris, “Oxygen free radicals in ischemic acute renal failure in the rat,” The Journal of Clinical Investigation, vol. 74, no. 4, pp. 1156–1164, 1984. View at Publisher · View at Google Scholar · View at Scopus
  57. H.-B. Peng, P. Libby, and J. K. Liao, “Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B,” The Journal of Biological Chemistry, vol. 270, no. 23, pp. 14214–14219, 1995. View at Publisher · View at Google Scholar · View at Scopus
  58. J. R. Matthews, C. H. Botting, M. Panico, H. R. Morris, and R. T. Hay, “Inhibition of NF-κB DNA binding by nitric oxide,” Nucleic Acids Research, vol. 24, no. 12, pp. 2236–2242, 1996. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Dijkstra, H. Moshage, and P. L. M. Jansen, “Blockade of NF-κB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease?” Scandinavian Journal of Gastroenterology, Supplement, vol. 37, no. 236, pp. 37–41, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. J. V. Bonventre and A. Zuk, “Ischemic acute renal failure: an inflammatory disease?” Kidney International, vol. 66, no. 2, pp. 480–485, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Furuichi, S. Kaneko, and T. Wada, “Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease,” Clinical and Experimental Nephrology, vol. 13, no. 1, pp. 9–14, 2009. View at Publisher · View at Google Scholar · View at Scopus